What we know
5 million debut fund. This fund is dedicated to backing early-stage startups that use artificial intelligence to advance drug development. 5 million for its first fund. Sahir Raoof, previously with SignalFire, leads the firm. The fund focuses on startups applying AI technologies to pharmaceutical research and development.
Why it matters
Artificial intelligence is increasingly seen as a transformative tool in drug discovery and development, attracting growing venture capital interest. Proximal Ventures’ debut fund targets this promising intersection, aiming to support innovations that could speed up and enhance pharmaceutical breakthroughs. Having an experienced investor like Sahir Raoof at the helm may help the fund identify and nurture high-potential AI-driven drug development startups.
What is still unknown
- Independent verification of the fund’s size, leadership, and investment focus beyond the initial report is not available. Details about the specific startups targeted or the fund’s investment strategy have not been disclosed. There is no information on the fund’s timeline for deploying capital or expected milestones.